ArticleAdvances in experimental medicine and biology2022
Microfluidics for Cancer Biomarker Discovery, Research, and Clinical Application.
Article in Advances in experimental medicine and biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- A Rapid Method Based on Colloidal Selenium Nanoparticle to Detect NT-proBNP Antigen in Serum for Monitoring Acute Heart Failure.International journal of nanomedicine · 2025Article
- Microfluidic biosensors for biomarker detection in body fluids: a key approach for early cancer diagnosis.Biomarker research · 2024Review
- Emerging Trends in Integrated Digital Microfluidic Platforms for Next-Generation Immunoassays.Micromachines · 2024Review
- Ensuring food safety: Microfluidic-based approaches for the detection of food contaminants.Analytical science advances · 2024Review
- Article
- Application of microfluidic technology based on surface-enhanced Raman scattering in cancer biomarker detection: A review.Journal of pharmaceutical analysis · 2023Review
- Smart Sensors and Microtechnologies in the Precision Medicine Approach against Lung Cancer.Pharmaceuticals (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Currently, cancer is the leading cause of death and its incidence and mortality is growing rapidly all over the world. One of the confounding factors contributing to the failure of conventional cancer diagnostics and treatment strategies is a high degree of intratumoral and intertumoral heterogeneity at the single-cell and molecular levels. Recent innovations in microfluidic techniques have revolutionized single-cell and single-molecule research and challenged the conventional definition of a "biomarker." Alongside classic cancer biomarkers such as circulating tumor DNA or circulating tumor cells (CTC), tumor cell heterogeneity, transcriptional and epigenetic cell states and their abundance in the tumor microenvironment have been demonstrated to impact disease progression and treatment response. Utilizing high-throughput, robust microfluidic techniques for the detection, isolation, and analysis of various cancer biomarkers, valuable information about the tumor can be obtained for clinical decision-making. This chapter presents clinically relevant advances of cancer biomarker research using microfluidics technology and identifies the emerging applications for disease diagnosis, monitoring, and personalized treatment.
Indexed as
Identifiers
35761005What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.